At a time when the world is gearing for the Coronavirus vaccine, NASSCOM CoE for IoT/AI, under its Healthcare initiative LHIF, organised a virtual conference themed ‘Vaccine Trials – Optimising the Supply Chain’.
At a time when the world is gearing for the Coronavirus vaccine, NASSCOM CoE for IoT/AI, under its Healthcare initiative LHIF, organized a virtual conference themed ‘Vaccine Trials – Optimising the Supply Chain’.
NEW DELHI: Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year.
Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year.
New Delhi, Dec 19 (SocialNews.XYZ) Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year.
New Delhi: Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year.
The Central government plans to vaccinate nearly 30 crore people in the first phase of the drive. It will be offered to one crore healthcare workers, along with two crore frontline and essential workers and 27 crore elderly, mostly above the age of 50 years with comorbidities.
NEW DELHI, DEC 19 : Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year.
New Delhi, Dec 19 – Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year.
Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to fabricate the Oxford-AstraZeneca vaccine, on Saturday stated that the nation would require a large funding of Rs 80,000 crore for distribution of the Covid vaccine for the following one 12 months.
New Delhi, Dec 19 : Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year.
New Delhi, Dec 19 : Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year.
New Delhi, Dec 19 (IANS) Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year.
